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Abstract
The aim of this study was to evaluate the clinical characteristics, predictors and outcomes of pneumococcal pneumonia developing pulmo-
nary complications and the distribution of pneumococcal serotypes. It was a prospective study including all adult patients admitted to the
Hospital Clinic of Barcelona, Spain (2001–2009) with the diagnosis of pneumococcal pneumonia. Microbiological investigation was systemat-
ically performed, including antimicrobial susceptibility and serotype distribution (only invasive strains isolated during 2006–2009). Compli-
cated pneumonia was deﬁned as the presence of one or more pulmonary complications: pleural effusion, empyema, or multilobar inﬁltrates.
We included 626 patients, and 235 (38%) had the following pulmonary complications: pleural effusion, 122 (52%); empyema, 18 (8%); and
multilobar inﬁltration, 151 (64%). Forty-six (20%) patients had more than one complication. Patients with pulmonary complications showed
a higher rate of intensive-care unit admission (34% vs. 13%, p <0.001), a higher rate of shock (16% vs. 7%, p <0.001), a longer length of stay
(9 days vs. 6 days, p <0.001), and a lower rate of penicillin resistance (14% vs. 25%, p 0.013), but similar mortality (9% vs. 8%). No signiﬁcant
differences were observed in the serotype distribution between complicated and uncomplicated pneumonia. Chronic obstructive pulmo-
nary disease (COPD) (OR 0.38, 95% CI 0.23–0.63; p <0.001) was a protective factor against pulmonary complications, whereas chronic
liver disease (OR 3.60, 95% CI 1.71–7.60; p 0.001), admission C-reactive protein level ‡18 mg/dL (OR 2.77, 95% CI 1.91–4.00; p <0.001)
and admission creatinine level >1.5 mg/dL (OR 2.01, 95% CI 1.31–3.08; p 0.001) were risk factors for pulmonary complications. Compli-
cated pneumonia was characterized by a more severe clinical presentation, but was not associated with increased mortality. Resistance to
antibiotics was lower in complicated cases. No signiﬁcant differences were observed in the serotype distribution between complicated and
uncomplicated pneumonia. In the multivariate analysis, COPD was a protective factor against pulmonary complications.
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Introduction
Streptococcus pneumoniae is the most frequent aetiological
agent of community-acquired pneumonia (CAP) [1]. Since
the addition of a heptavalent protein–polysaccharide conju-
gate vaccine (PCV7) to the routine childhood vaccination
schedule, numerous studies have documented declining rates
of colonization with PCV7 serotypes and a lower incidence
of PCV7-type invasive pneumococcal disease (IPD) among
young children and adults. Despite the effectiveness of the
conjugate vaccine, the emergence of IPD caused by non-
vaccine serotypes has been reported [2–4].
Most cases of adult pneumococcal pneumonia are self-lim-
iting, and patients fully recover. A subset of patients have a
more complicated course associated with pulmonary compli-
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cations, including pleural effusion, empyema, and multilobar
consolidation or cavitations.
Among potential complications, pleural effusion is very fre-
quent, as up to 57% of hospitalized pneumonia patients may
develop it [5,6]. Moreover, it is considered to be an indica-
tor of severity of pneumonia, and is clearly associated with
an increased risk of treatment failure [7–9].
The occurrence of empyema is one of the main factors
associated with poor outcome in CAP [10], and is a frequent
cause of prolonged treatment (medical and surgical) and hos-
pital stay [11], and even of treatment failure [7,8].
Multilobar consolidation is one of the minor criteria for
deﬁning severe CAP and evaluating the need for intensive-
care unit (ICU) admission, and is associated with treatment
failure [7,8,10]. Moreover, different authors have found that
multilobar inﬁltration is an independent risk factor for
increased mortality in CAP [9,12]. Adults with these compli-
cations often require prolonged hospitalization, and are at
risk of signiﬁcant and long-lasting morbidity [5,9].
Although the overall burden of IPD has decreased, the inci-
dence of complicated pneumonia may be rising. Several stud-
ies have shown an increase in the frequency of pulmonary
complications among children [13–15]. This increase does not
appear to be related to the concurrent increase in the fre-
quency of penicillin-resistant S. pneumoniae, but does appear
to be related to the introduction of virulent clones expressing
non-vaccine serotypes, especially serotype 1. Serotype distri-
butions may be relevant in this trend. Likewise, host factors
such as age, gender and the presence of comorbidities have
been related to invasive pneumococcal pneumonia and may be
risk factors for the development of complicated pneumonia.
On the other hand, data on the clinical manifestations in an
adult population with complicated pneumococcal pneumonia
are limited. This study was undertaken to evaluate the clinical
characteristics and outcomes of adults with pneumococcal
pneumonia, especially those with pulmonary complications.
Materials and Methods
Study population
The study population consisted of adults consecutively admit-
ted to the Hospital Clinic of Barcelona (Spain), an 800-bed
third-level hospital covering an urban population of 540 000
inhabitants, between 2001 and 2009, with a diagnosis of
pneumococcal pneumonia.
At the initial visit, patients underwent a complete clinical his-
tory and physical examination. Patients were stratiﬁed into risk
classes with the validated prediction rule calculated according
to Pneumonia Severity Index (PSI) scores. Empirical antibiotic
treatment was administered according to hospital guidelines.
All surviving patients were visited at 30–40 days after discharge.
Microbiological evaluation and diagnostic criteria
Regular sampling included sputum specimens, two blood cul-
tures and urine samples for detection of S. pneumoniae (Binax
Now S. pneumoniae Urinary Antigen Test; Emergo Europe,
The Hague, The Netherlands) and Legionella pneumophila se-
rogroup 1 (Binax Now L. pneumophila Urinary Antigen Test;
Trinity Biotech, Bray, Ireland). Samples from pleural ﬂuid
puncture, tracheobronchial aspiration and blind bronchoalve-
olar lavage were obtained according to the judgement of the
attending physician.
The diagnosis of pneumonia was established in the pres-
ence of clinical symptoms and a new inﬁltrate on the chest
radiograph and no alternative diagnosis during follow-up. The
aetiology of pneumococcal pneumonia was determined in
cases with a positive valid sputum culture, positive blood cul-
ture, positive pleural ﬂuid and transthoracic needle aspiration
cultures, positive urinary antigen for S. pneumoniae, bacterial
growth in cultures of tracheobronchial aspiration specimens
of ‡105 CFU/mL, bacterial growth in cultures of phosphate-
buffered saline of ‡10 CFU/mL, and bacterial growth in cul-
tures of bronchoalveolar lavage specimens of ‡104 CFU/mL.
Pneumococcal isolates were identiﬁed with standard
microbiological methods. All strains isolated from normally
sterile sites were routinely frozen at )70C in skimmed milk.
Later, molecular serotype detection was performed with a
published Multiplex real-time assay [9] at the Molecular
Microbiology Department, Hospital Sant Joan de Deu, Barce-
lona. This PCR procedure allows differentiation of 24 sero-
types (1, 3, 5, 4, 6A, 6B, 7F/A, 8, 9V/A/N/L, 14, 15B/C, 18C/
B, 19A, 19F/B/C, 23F and 23A). Strains not typeable by real-
time PCR were consecutively serotyped with the Quellung
reaction, using rabbit polyclonal antisera from the Statens
Serum Institute (Copenhagen, Denmark) at the National
Pneumococcus Reference Centre (Majadahonda, Madrid). Se-
rotyping was performed only in invasive strains isolated dur-
ing the period from 2006 to 2009.
Strains were initially screened for susceptibility to antimi-
crobial agents with Sensititre (Trek Diagnostic Systems, East
Grinstead, UK). Penicillin susceptibility and other antibiotic
susceptibilities were deﬁned according to the 2008 break-
points of the CLSI [16].
Deﬁnitions of pulmonary complications
Complicated pneumonia was deﬁned as the presence of one
or more of the following pulmonary complications: pleural
effusion, empyema, or multilobar inﬁltrates. We included
only meaningful pleural effusions in which thoracocentesis
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was performed and pleural ﬂuid was obtained. Pleural empy-
ema was diagnosed if (i) the Gram stain was positive or a
pathogen was cultured from pleural ﬂuid, or (ii) at least two
of the following criteria were fulﬁlled by pleural ﬂuid analysis:
glucose £40 mg/dL, lactate dehydrogenase ‡1000 u/L,
pH £7.2, and white blood cell count of 10 000 cells/mL. Mul-
tilobar pneumonia was deﬁned as a chest X-ray inﬁltrate
involving two or more lobes [2].
Exclusion criteria were as follows: (i) severe immunosup-
pression, such as solid organ or bone marrow transplantation
or AIDS, receiving chemotherapy or other immunosuppres-
sive drugs (>20 mg of prednisone equivalent per day for
2 weeks or more), or asplenia; (ii) hospitalization in the
preceding 21 days; (iii) active tuberculosis; and (iv) health-
care-associated pneumonia according to American Thoracic
Society/Infectious Diseases Society of America guidelines [7].
Patients were categorized into two groups on the basis of
the presence or absence of pulmonary complications: uncom-
plicated and complicated pneumonia.
Statistical analysis
Categorical variables were described by frequencies and per-
centages, and continuous variables by means and standard
deviations, or the median and interquartile range for data
that were not normally distributed (Kolmogorov–Smirnov
test). Categorical variables were compared by use of the chi-
square test or Fisher’s exact test where appropriate. Contin-
uous variables were compared by use of Student’s t-test
once normality was demonstrated; otherwise, the non-para-
metric Mann–Whitney U-test was performed.
Univariate and multivariate logistic regression analyses
were performed to identify variables predictive of patients
with pulmonary complications (dependent variable). The vari-
ables analysed univariately were: age, gender, smoking, alco-
hol consumption, previous antibiotic use, inﬂuenza vaccine,
pneumococcal vaccine, systemic corticosteroids, chronic
obstructive pulmonary disease (COPD), chronic cardiovascu-
lar disease, diabetes mellitus, neurological disease, chronic
renal failure, chronic liver disease, bacteraemia, creatinine,
C-reactive protein (CRP) level, and white blood cell count.
Interactions between variables were speciﬁcally searched for.
Variables that showed a signiﬁcant result univariately (p <0.1)
were included in the multivariate logistic regression back-
ward stepwise model. Variables that were highly correlated
were excluded from multivariate analyses. The Hosmer–
Lemeshow goodness-of-ﬁt test was performed to assess the
overall ﬁt of the model [17]. All tests were two-tailed, and
signiﬁcance was set at 5%. All analyses were performed with
SPSS version 16.0 for Windows (SPSS, Chicago, IL, USA).
Results
General characteristics of the study population
A total of 626 patients were included during the study per-
iod from 2001 to 2009. The mean age was 63.6 ± 18.9 years
(289 patients (46%) were aged £65 years), and 355 (57%) of
the patients were male.
On admission, the patients were classiﬁed by PSI score as
being in the low-risk group (I–III) (n = 299, 48%), the inter-
mediate-risk group (IV) (n = 214, 34%), and the high-risk
group (V) (n = 113, 18%). Fifty-four patients (9%) died within
30 days of admission. Table 1 summarizes the main charac-
teristics of the 626 patients.
Pulmonary complications
Of the 626 patients, 235 (38%) had pulmonary complications,
distributed as follows: pleural effusion, 122 (52%); empyema,
18 (8%); and multilobar inﬁltration, 151 (62%). Forty-six
(20%) had more than one of the pulmonary complications.
The characteristics of the patients with complicated and
uncomplicated pneumonia are summarized in Tables 2–5.
TABLE 1. Demographic and clinical characteristics of
patients with pneumococcal pneumonia
General characteristics
Pneumococcal
pneumonia (N = 626)
Demographics
Age (years), mean (SD) 63.6 (18.9)
Sex (male), n (%) 355 (57)
Current smoking, n (%) 198 (31.9)
Current alcohol abuse, n (%) 104 (16.8)
Previous antibiotic, n (%) 85 (16.0)
Inﬂuenza vaccine, n (%) 213 (39.1)
Pneumococcal vaccine, n (%) 79 (14.6)
Inhaled corticosteroid, n (%)a 133 (21.3)
Systemic corticosteroid, n (%)a 13 (2.2)
Comorbidity, n (%)
Chronic respiratory disease 275 (44.2)
Bronchiectasis 64 (10.3)
COPD 130 (21.0)
Asthma 41 (6.6)
Other 40 (6.4)
Chronic cardiovascular disease, n (%) 84 (13.5)
Diabetes mellitus, n (%) 105 (16.9)
Neurological disease, n (%) 87 (14.0)
Chronic renal failure, n (%) 31 (5.0)
Chronic liver disease, n (%) 38 (6.1)
Pulmonary complications, n (%)b
Multilobar inﬁltration 151 (64.2)
Pleural effusion 122 (51.9)
Empyema 18 (7.6)
PSI I–III, n (%) 299 (47.8)
PSI IV–V, n (%) 327 (52.2)
Bacteraemia, n (%) 206 (32.9)
ICU admission, n (%) 132 (21.1)
Mechanical ventilation, n (%) 55 (9.8)
Length of hospital stay (days), median (IQR) 9.4 ± 6
30-day mortality, n (%) 54 (8.7)
COPD, chronic obstructive pulmonary disease; ICU, intensive-care unit; IQR, in-
terquartile range; PSI, Pneumonia Severity Index; SD, standard deviation.
aTreatment before admission for pneumonia episode.
bForty-six patients had more than one pulmonary complication.
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The main parameters of clinical severity (PSI, ICU, mechani-
cal ventilation (MV), etc.) showed a homogeneous distribu-
tion among patients with different pulmonary complications,
with the exception of bacteraemia, which showed a tendency
to be more frequent among patients with multilobar involve-
ment (Tables 2–5). A higher proportion of patients aged
>65 years was observed in the complicated pneumonia
group (47% vs. 58%, p 0.010). There were no differences in
smoking or alcohol consumption between the two groups.
There was a difference in temperature at admission
TABLE 2. Characteristics of pati-
ents with complicated community-
acquired pneumonia (CAP) and
uncomplicated CAP
Variable
Complicated
CAP (N = 235)a
Uncomplicated
CAP (N = 391)a
p-Value
Demographics
Age (years), mean (SD) 61.6 (18.5) 64.9 (19.0) 0.027
Age >65 years, n (%) 111 (47.2) 226 (57.8) 0.010
Sex (male), n (%) 129 (54.9) 226 (57.8) 0.48
Current smoking, n (%) 83 (35.8) 115 (29.6) 0.11
Current alcohol abuse, n (%) 47 (20.2) 57 (14.8) 0.07
Previous antibiotic, n (%) 34 (17.4) 51 (15.0) 0.47
Inﬂuenza vaccine, n (%) 64 (31.4) 149 (43.7) 0.004
Pneumococcal vaccine, n (%) 23 (11.3) 56 (16.5) 0.10
Inhaled corticosteroid, n (%)b 29 (12.4) 104 (26.7) <0.001
Systemic corticosteroid, n (%)b 3 (1.4) 10 (2.7) 0.30
Comorbidity, n (%)
Chronic respiratory disease <0.001
Bronchiectasis 26 (11.2) 38 (9.8) 0.58
COPD 28 (12.0) 102 (26.2) <0.001
Asthma 19 (8.2) 22 (5.7) 0.22
Other 28 (7.2) 12 (5.2) 0.31
Chronic cardiovascular disease, n (%) 25 (10.7) 59 (15.1) 0.12
Diabetes mellitus, n (%) 34 (14.7) 71 (18.3) 0.25
Neurological disease, n (%) 33 (14.1) 54 (14.0) 0.97
Chronic renal failure, n (%) 9 (3.9) 22 (5.7) 0.32
Chronic liver disease, n (%) 22 (9.4) 16 (4.1) 0.008
Clinical manifestations, n (%)
Fever 215 (91.9) 336 (85.9) 0.026
Dyspnoea 191 (81.3) 267 (68.3) <0.001
Chest pain 146 (62.1) 215 (55.1) 0.09
Acute renal failure 54 (23.4) 41 (10.6) <0.001
Shock 37 (15.9) 28 (7.2) <0.001
Clinical ﬁndings
Temperature (C), median (IQR) 37.6 (1.6) 38.0 (1.5) 0.013
Systolic blood pressure (mmHg), median (IQR) 120.0 (39.0) 124.5 (34.5) 0.08
Laboratory ﬁndings
Creatinine (mg/dL), median (IQR) 1.1 (0.8) 1.1 (0.5) 0.11
Creatinine >1.5 mg/dL, n (%) 62 (26.4) 62 (15.9) 0.001
C-reactive protein level (mg/dL), median (IQR) 25.1 (18.3) 17.4 (19.4) <0.001
C-reactive protein level ‡18 mg/dL, n (%) 166 (71.6) 182 (48.0) <0.001
WBC count (109 cell/L), median (IQR) 14.9 (10.3) 15.9 (9.0) 0.028
Saturated O2 (%), median (IQR) 92.0 (6.9) 93.9 (5.5) <0.001
Saturated O2 <92%, n (%) 81 (46.8) 84 (32.7) 0.003
PaO2/FiO2 ratio, median (IQR) 266.7 (71.4) 287.1 (89.9) <0.001
PaO2/FiO2 ratio <200, n (%) 28 (14.5) 17 (5.4) <0.001
PSI IV–V, n (%) 134 (57.0) 193 (49.4) 0.06
Bacteraemia, n (%) 93 (39.6) 113 (28.9) 0.006
ICU admission, n (%) 80 (34.0) 52 (13.3) <0.001
Mechanical ventilation, n (%) 32 (15.5) 23 (6.5) <0.001
Length of hospital stay (days), median (IQR) 9.0 (9.0) 6.0 (6.0) <0.001
30-day mortality, n (%) 22 (9.4) 32 (8.2) 0.62
COPD, chronic obstructive pumonary disease; ICU, intensive-care unit; IQR, interquartile range; PSI, Pneumonia
Severity Index; SD, standard deviation; WBC, white blood cell.
aComplicated CAP caused by multilobar involvement (two or more lobes) in 151 cases (64%), pleural effusion in 122
cases (52%), and empyema in 18 cases (8%). Forty-six (20%) patients had more than one complication.
bTreatment before admission for pneumonia episode.
TABLE 3. Patients with multilobar involvement
Variable
Multilobar involvement
(N = 155)
PSI IV–V, n (%) 89 (58.9)
Bacteraemia, n (%) 65 (43.0)
ICU admission, n (%) 57 (37.7)
Mechanical ventilation, n (%) 28 (21.5)
Length of hospital stay (days), median (IQR) 9.0 (9.0)
30-day mortality, n (%) 18 (11.9)
ICU, intensive-care unit; IQR, interquartile range; PSI, Pneumonia Severity Index.
TABLE 4. Patients with pleural effusion
Variable
Pleural effusion
(N = 122)
PSI IV–V, n (%) 72 (59.0)
Bacteraemia, n (%) 40 (32.8)
ICU admission, n (%) 44 (36.1)
Mechanical ventilation, n (%) 13 (12.0)
Length of hospital stay (days), median (IQR) 10.0 (9.0)
30-day mortality, n (%) 10 (8.2)
ICU, intensive-care unit; IQR, interquartile range; PSI, Pneumonia Severity Index.
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(p 0.013). CRP level ‡18 mg/dL (p <0.001) and creatinine
level >1.5 mg/dL (p 0.001) were higher in patients with com-
plicated pneumonia. However, patients with complicated
pneumonia had fewer comorbidities (<1 comorbidity) than
patients with uncomplicated pneumonia (57% vs. 69%,
p 0.003), and a lower rate of inﬂuenza vaccination (p 0.004).
Complicated pneumonia patients had a longer length of
hospital stay (p <0.001), more frequent admission to the
ICU (p <0.001), more frequent shock (p <0.001) and longer
time to clinical stability (8 days vs. 5 days, p <0.001) than
uncomplicated pneumonia patients. The mortality rate was
similar in both groups (9% vs. 8%), despite the higher fre-
quency of bacteraemia and shock observed in complicated
cases (p 0.005 and p 0.001, respectively). The analysis of
mortality did not show signiﬁcant differences between
groups when sthe different pulmonary complications were
split (multilobar, 18 (12%); pleural effusion, 10 (8%); and
empyema, 2 (11%)) (Tables 2–5).
Diagnosis of pneumococcal pneumonia resistance to antibi-
otics and serotypes
The S. pneumoniae antigen was detected in 404 patients from
urine (65%), and was isolated by culture in 221 (35%) sterile
samples (203 from blood and 18 from pleural ﬂuid). In addi-
tion, S. pneumoniae was isolated in 13 (2%) patients from bron-
chial aspirate sample and in 128 (20%) from sputum samples.
MIC testing was performed for 333 of 362 (92%) S. pneu-
moniae isolates. A total of 69 pneumococcal isolates showed
some degree of penicillin non-sensitivity; resistance was
intermediate (MIC 4 mg/L) in 38 and high (MIC ‡8 mg/L) in
31. In addition, 56 pneumococcal isolates were non-suscepti-
ble to erythromycin (resistance was intermediate
(MIC 0.5 mg/L) in two and high (MIC ‡1 mg/L) in 54). The
rates of penicillin and erythromycin resistance were almost
two-fold higher in uncomplicated pneumonia cases (p 0.036
and, p 0.027, respectively) (Table 6).
Eighty-four of 221 (38%) invasive isolates were available
for serotyping (2006–2009 period). The most frequent sero-
types in this population were 1 (n = 27, 32%), 19A (n = 15,
18%), 3 (n = 7, 8%), 14 (n = 5, 6%), 7F (n = 5, 6%), and 5
(n = 4, 5%), as summarized in Table 7. No signiﬁcant differ-
ences were observed in the serotype distribution of compli-
cated and uncomplicated pneumonia. However, a non-
signiﬁcant trend for a higher frequency of serotype 19A was
observed in complicated pneumonia patients. Serotypes cov-
ered by the PCV7 vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F)
represented only 13% of all serotypes; 87% were not
included in the vaccine. There were no statistically signiﬁcant
differences (p 0.42) when different serotypes and pulmonary
complications were compared (PCV7 serotype vs. non-PCV7
serotypes).
Predictors of complicated pneumonia
Univariate analysis revealed the following protective factors
against complicated pneumonia: age >65 years, presence of
COPD, absence of chronic liver disease, absence of bactera-
emia, low CRP levels (<18 mg/dL), and low creatinine levels
(£1.5 mg/dL) (Table 8).
In multivariate analysis, a protective association of compli-
cated pneumonia was evident in patients with COPD
(OR 0.38, 95% CI 0.23–0.63; p <0.001). Chronic liver disease
(OR 3.60, 95% CI 1.71–7.60; p 0.001), CRP level ‡18 mg/dL
TABLE 5. Patients with empyema
Variable Empyema (N = 18)
PSI IV–V, n (%) 10 (55.6)
Bacteraemia, n (%) 4 (22.2)
ICU admission, n (%) 7 (38.9)
Mechanical ventilation, n (%) 2 (14.3)
Length of hospital stay (days), median (IQR) 13.5 (9.0)
30-day mortality, n (%) 2 (11.1)
ICU, intensive-care unit; IQR, interquartile range; PSI, Pneumonia Severity Index.
TABLE 6. Results of penicillin and
erythromycin resistance testing of
Streptococcus pneumoniae isolates
from patients with complicated or
uncomplicated pneumococcal
pneumonia
Penicillin resistance (MIC; mg/mL)a
Complicated (N = 135) Uncomplicated (N = 198)
p-Value
0.036No. of isolates (%) No. of isolates (%)
Susceptible, MIC £2 116 (85.9) 148 (74.7) 0.013
Intermediately susceptible, MIC 4 9 (6.7) 29 (14.6) 0.024
Resistant, MIC ‡8 10 (7.4) 21 (10.6) 0.32
Erythromycin resistance (MIC; mg/mL)b
Complicated (N = 134) Uncomplicated (N = 194) p-Value
0.027
No. of isolates (%) No. of isolates (%)
Susceptible, MIC £0.25 117 (87.3) 155 (79.9) 0.08
Intermediately susceptible, MIC 0.5 2 (1.5) 0 (0) 0.17
Resistant, MIC ‡1 15 (11.2) 39 (20.1) 0.033
aFor penicillin resistance, data were available for 333 patients.
bFor erythromycin resistance, data were available for 328 patients.
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(OR 2.77, 95% CI 1.91–4.00; p <0.001) and creatinine
level >1.5 mg/dL (OR 2.01, 95% CI 1.31–3.08; p 0.001) were
risk factors for pulmonary complications (Table 8).
Antibiotic treatment
Data on antibiotic treatment was available for 620 (99%)
patients, as follows: b-lactam plus macrolide (241, 39%); b-
lactam plus ﬂuoroquinolone (168, 27%); ﬂuoroquinolone
alone (136, 22%); b-lactam alone (52, 8%); macrolide plus ﬂu-
oroquinolone (six, 1%); macrolide alone (two, 0.3%); and
other combinations (15, 2%) (Table 9).
A b-lactam plus a ﬂuoroquinolone was more frequently
(p <0.001) administered to patients with pulmonary compli-
cations. However, a ﬂuroquinolone as monotherapy was less
frequently administered (p <0.001) (Table 9). We did not
ﬁnd initially inadequate antibiotic treatments in the popula-
tion for which an antibiogram was available.
Discussion
The most important ﬁndings of our study are as follows: (i)
pulmonary complications were frequent (38%) in patients
with pneumococcal CAP; (ii) although mortality was similar
between the groups, patients with pulmonary complications
presented a higher rate of bacteraemia, shock, and need for
MV, with a subsequent increase in the rate of ICU admission
and length of stay; (iii) patients with pulmonary complications
had a lower rate of penicillin and macrolide resistance; (iv)
pulmonary complications were not signiﬁcantly different
when PCV7 serotypes were compared with non-PCV7 sero-
types; (v) and COPD was a protective factor against pulmo-
nary complications.
TABLE 7. Serotype distribution of 84 Streptococcus pneumo-
niae isolates (years 2006–2009)
Pneumococcal
"serotype
Complicated
CAP (N = 52), n (%)
Uncomplicated
(N = 32), n (%)
1 17 (32.6) 10 (31.2)
3 5 (9.6) 2 (6.2)
4 2 (3.8) 1 (3.1)
5 3 (5.7) 1 (3.1)
6A 1 (1.9) 0 (0)
7F 1 (1.9) 4 (12.5)
8 0 (0) 1 (3.1)
9N 0 (0) 1 (3.1)
9A 1 (1.9) 0 (0)
9V 2 (3.8) 0 (0)
10A 1 (1.9) 0 (0)
11F 0 (0) 1 (0)
12F 3 (5.7) 0 (0)
14 4 (7.6) 1 (3.1)
19A 11 (21.1) 4 (12.5)
19F 0 (0) 1 (3.1)
22F 0 (0) 1 (3.1)
24F 0 (0) 3 (9.3)
29 0 (0) 1 (3.1)
31 1 (1.9) 0 (0)
CAP, community-acquired pneumonia.
TABLE 8. Signiﬁcant univariate
and multivariate logistic regres-
sion analyses of complicated pul-
monary pneumonia
Variable
Univariate Multivariatea
OR 95% CI p-Value OR 95% CI p-Value
Age >65 years 0.65 0.47–0.90 0.010 – – –
Pneumococcal vaccine 0.65 0.38–1.09 0.099 – – –
Chronic respiratory diseaseb – – 0.001 – – 0.001
None 1 – – 1 – –
Bronchiectasis 0.92 0.53–1.58 0.76 0.84 0.47–1.49 0.55
COPD 0.37 0.23–0.59 <0.001 0.38 0.23–0.63 <0.001
Asthma 1.16 0.61–2.22 0.65 1.43 0.72–2.86 0.31
Other 0.58 0.28–1.17 0.13 0.51 0.24–1.10 0.084
Chronic liver disease 2.42 1.24–4.71 0.009 3.60 1.71–7.60 0.001
Bacteraemia 1.61 1.15–2.27 0.006 – – –
Creatinine >1.5 mg/dL 1.90 1.27–2.82 0.002 2.01 1.31–3.08 0.001
C-reactive protein ‡18 mg/dL 2.72 1.92–3.86 <0.001 2.77 1.91–4.00 <0.001
COPD, chronic obstructive pulmonary disease.
aHosmer–Lemeshow goodness-of-ﬁt test: p 0.57.
bThe p-value corresponds to differences between the ﬁve groups (none, bronchiectasis, COPD, asthma, or other
chronic respiratory disease). The OR and 95% CI of bronchiectasis, COPD, asthma and other chronic respiratory dis-
ease are related to cases with no chronic respiratory disease.
TABLE 9. Initial antibiotic treatment by study group
Antibiotic treatment
Complicated
CAP (N = 235),
n (%)
Uncomplicated
CAP (N = 391),
n (%)
p-Value
b-Lactam + macrolide 90 (38.3) 151 (38.6) 0.94
b-Lactam + ﬂuoroquinolone 85 (36.2) 83 (21.2) <0.001
Macrolide + ﬂuoroquinolone 1 (0.4) 5 (1.3) 0.42
Other combinations 4 (1.7) 11 (2.8) 0.38
Fluoroquinolone monotherapy 32 (13.6) 104 (26.6) <0.001
b-Lactam monotherapy 22 (9.4) 30 (7.7) 0.46
Macrolide monotherapy 0 (0) 2 (0.5) 0.53
Unknown therapy 1 (0.4) 5 (1.3) 0.42
b-Lactams include: ceftriaxone (1 or 2 g per day for 7 days); amoxycillin–clavul-
anic (1 g every 8 h for 7 days); cefotaxime (1 or 2 g every 8 h for 7 days). Flu-
oroquinolones include: levoﬂoxacin (500 mg every 12 h or 500 mg every 24 h
for 7–10 days); moxiﬂoxacin (400 mg every 24 h for 5–7 days). Macrolides
include: azithromycin (500 mg per day for 3–6 days). Other combinations
include: ceftriaxone (1 g every 24 h) plus clindamicin (600 mg every 8 h); amika-
cin (15 mg/kg every 24 h) plus levoﬂoxacin (500 mg every 24 h); and merope-
nem (1 g every 6–8 h) plus levoﬂoxacin (500 mg every 24 h).
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In the present study, we found that patients with pneumo-
coccal pneumonia had 38% of pulmonary complications as
deﬁned. This is the ﬁrst study evaluating the clinical impact
of pulmonary complications in hospitalized adults with pneu-
mococcal pneumonia. Other publications have reported
these complications only erratically. For example, in a previ-
ous study in adults, empyema was reported in 2% [18], and
another study reported multilobar inﬁltrates in 37% [19].
Our study characterized a population of pneumococcal CAP
patients who developed pulmonary complications, showing
that they were younger and had fewer comorbidities (espe-
cially COPD) than patients without pulmonary complications.
The concept of grouping pulmonary complications together
comes from paediatricians who have studied children with
and without complications of pneumococcal pneumonia [20].
Indeed, two previous studies described several risk factors
associated with an increased risk of pulmonary complications
in children as follows: younger age, black race, low weight,
and anaemia [13,20]. In our study, all of the analysed pulmo-
nary complications clearly showed a positive association with
parameters of CAP severity such as ICU admission and
length of hospital stay. This ﬁnding supports our motivation
to investigate prognostic factors for the development of pul-
monary complications.
Patients with complicated CAP had a lower rate of COPD
and a higher rate of chronic liver disease. Other differential
characteristics of complicated pneumonia were a higher
inﬂammatory response (as assessed by higher CRP levels)
and a higher percentage of bacteraemia, shock, ICU admis-
sion and MV than in uncomplicated pneumonia. The length
of stay was higher for patients with complicated pneumonia,
but the mortality rate did not signiﬁcantly differ between the
two study groups (9% vs. 8%). It is probable that all of these
clinical and biological characteristics will, in the future, help
clinicians to identify patients who may need a higher degree
of monitoring and/or ICU care [21].
In the present study, we found that the rates of resistance
to penicillin and macrolide were signiﬁcantly higher in
patients without pulmonary complications. A reduced rate of
antibiotic resistance has also been observed in previous stud-
ies on adult patients with pneumococcal bacteraemia, in
recent studies of adult patients with septic shock and of chil-
dren with pulmonary complications of pneumococcal pneu-
monia [20,22].
We were able to determine the pneumococcal serotype
in 84 invasive strains. On comparison of serotype distribu-
tion in the two population groups, we found no statistically
signiﬁcant differences (p 0.42) in relation to pulmonary com-
plications according to serotype group (PCV7 serotype vs.
non-PCV7 serotypes); however, we found a trend for a
higher rate of serotype 19A in patients with complicated
pneumonia. Other studies have found that serotype 19A is
more frequent among adults and children with IPD and com-
plicated pneumococcal pneumonia [4,22]. In a landmark
study, the incidence of IPD in adults was found to have
decreased since the PCV7 vaccine was introduced. In con-
trast, the incidence of more virulent serotypes (3 and 19A)
had increased in parallel [23]. A recently published study by
Garcia-Vidal et al. [22] showed that serotype 3 was more
frequent in patients with pneumococcal pneumonia present-
ing with shock. All of these data are crucial for the devel-
opment of new vaccines. Fortunately, the new conjugate
13-valent pneumococcal vaccine includes serotypes 1, 3, and
19A, and is currently being tested in adults aged over
65 years [24].
Chronic liver disease was one of the factors associated
with an increased risk of pulmonary complications in the mul-
tivariate analysis. Another study by our group has shown that
chronic liver disease is a risk factor for complications and
poor outcomes [25]. An elevated CRP level (‡18 mg/dL) at
admission was also found to be a risk factor for the develop-
ment of pulmonary complications. Chalmers et al. [26] found
that low admission CRP levels were associated with negative
predictive value for 30-day mortality, MV, inotropic support,
and complicated pneumonia. In the other hand we found that
eleveated creatinine (>1.5mg/dL) at atmission was another
risk factor for pulmonary complications. This parameter is a
marker of a bad outcome, as has been described previously
[27]. In the same analysis, we found that only COPD was a
protective factor against the development of pulmonary com-
plications. Why COPD is a protective factor against pulmo-
nary complications is difﬁcult to explain. However, in a
recent cellular study by our group [28], we observed the
activation of different phenotype macrophages in CAP with
and without COPD, indicating different inﬂammatory
responses. This different type of activation induces different
inﬂammatory responses, and may be involved in the better
outcome of CAP observed in some studies when COPD pre-
sents simultaneously [28]. Similarly, Strassburg et al. [29]
found decreased apoptosis of pulmonary neutrophils in
COPD patients with CAP, indicating an increased inﬂamma-
tory response to the bacterial load in these patients. COPD
was also found to be a protective factor against non-respond-
ing pneumonia in another study from our group investigating
factors associated with treatment failure in CAP [8].
Investigation of antibiotic treatment in our population
showed a signiﬁcantly higher rate of b-lactam plus ﬂuoroqui-
nolone treatment in patients with complicated CAP. In con-
trast, we observed a higher rate of ﬂuoroquinolone
monotherapy in patients with uncomplicated CAP. These
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differences can probably be explained by the disease severity,
which inﬂuenced clinicians to use a potent antibiotic combi-
nation for complicated CAP and monotherapy for uncompli-
cated CAP. In the study period, our hospital routinely
followed the recommendations of the Spanish Society of Pul-
monology and Thoracic Surgery for the empirical treatment
of CAP [30]. Following these guidelines (b-lactam plus mac-
rolide or quinolone as monotherapy), we found that initial
antibiotic treatment was adequate in patients for whom an
antibiogram was available.
The strengths of our study are as follows: (i) a large popula-
tion of consecutive patients included over a period of 9 years;
(ii) the application of the concept of pulmonary complications
in adults for the ﬁrst time in CAP, following what has been
previously published for the paediatric population [14] the
concept of complicated pneumonia could be debated but in
our opinion it represents a CAP subpopulation that can be dis-
tinguished speciﬁcally; and (iii) the study of antibiotic resistance
in most of the strains, and serotype information for the last
4 years. A limitation of the study is the lack of information
about the time to the ﬁrst dose of antibiotic, a variable that
may potentially inﬂuence mortality. Moreover, serotyping
results were limited to the years 2006–2009.
In summary, our study describes a subpopulation of hospi-
talized pneumococcal pneumonia patients in whom the mor-
tality did not differ despite the higher severity of pneumonia.
COPD as a comorbidity was the only protective factor
against pulmonary complications. Finally, no signiﬁcant differ-
ences were observed between the serotype distributions of
complicated and uncomplicated pneumonia.
Financial Disclosure
None.
Acknowledgements
For logistic support: 2009 Support to Research Groups of Ca-
talunya 911; Ciber de Enfermedades Respiratorias (CibeRes
CB06/06/0028); Ciberes es una iniciativa del Instituto de Salud
Carlos III—Ministerio de Ciencia e Innovacion, Spain; and Insti-
tut de investigaciones Biome´dicas August Pi i Sunyer.
Transparency Declaration
None of the authors have any conﬂict of interests to
declare.
References
1. Van Der PT, Opal SM. Pathogenesis, treatment, and prevention of
pneumococcal pneumonia. Lancet 2009; 374: 1543–1556.
2. Goldbart AD, Leibovitz E, Porat N et al. Complicated community
acquired pneumonia in children prior to the introduction of the pneu-
mococcal conjugated vaccine. Scand J Infect Dis 2009; 41: 182–187.
3. Munoz-Almagro C, Jordan I, Gene A et al. Emergence of invasive
pneumococcal disease caused by nonvaccine serotypes in the era of
7-valent conjugate vaccine. Clin Infect Dis 2008; 46: 174–182.
4. Ardanuy C, Tubau F, Pallares R et al. Epidemiology of invasive pneu-
mococcal disease among adult patients in Barcelona before and after
pediatric 7-valent pneumococcal conjugate vaccine introduction,
1997–2007. Clin Infect Dis 2009; 48: 57–64.
5. Light RW, Girard WM, Jenkinson SG et al. Parapneumonic effusions.
Am J Med 1980; 69: 507–512.
6. Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates
of parapneumonic effusions in pneumococcal pneumonia. Chest 1978;
74: 170–173.
7. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases
Society of America/American Thoracic Society consensus guidelines
on the management of community-acquired pneumonia in adults. Clin
Infect Dis 2007; 44 (suppl 2): S27–S72.
8. Menendez R, Torres A, Zalacain R et al. Risk factors of treatment
failure in community acquired pneumonia: implications for disease
outcome. Thorax 2004; 59: 960–965.
9. Lim WS, Baudouin SV, George RC et al. BTS guidelines for the man-
agement of community acquired pneumonia in adults: update 2009.
Thorax 2009; 64 (suppl 3): iii1–iii55.
10. Roson B, Carratala J, Fernandez-Sabe N et al. Causes and factors
associated with early failure in hospitalized patients with community-
acquired pneumonia. Arch Intern Med 2004; 164: 502–508.
11. Chalmers JD, Singanayagam A, Murray MP et al. Risk factors for com-
plicated parapneumonic effusion and empyema on presentation to
hospital with community-acquired pneumonia. Thorax 2009; 64: 592–
597.
12. Garcia-Vidal C, Fernandez-Sabe N, Carratala J et al. Early mortality in
patients with community-acquired pneumonia: causes and risk factors.
Eur Respir J 2008; 32: 733–739.
13. Obando I, Munoz-Almagro C, Arroyo LA et al. Pediatric parapneu-
monic empyema, Spain. Emerg Infect Dis 2008; 14: 1390–1397.
14. Tan TQ, Mason EO Jr, Barson WJ et al. Clinical characteristics and
outcome of children with pneumonia attributable to penicillin-suscep-
tible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics
1998; 102: 1369–1375.
15. Byington CL, Hulten KG, Ampofo K et al. Molecular epidemiology of
pediatric pneumococcal empyema from 2001 to 2007 in Utah. J Clin
Microbiol 2010; 48: 520–525.
16. National Committee for Clinical Laboratory Standards. Performance
standards for antimicrobial susceptibility testing: eighteenth informational
supplement. CLSI document M100-S18. Wayne, PA: CLSI, 2008.
17. Hosmer D, Lemeshow S. Applied logistic regression. New York: Wiley,
1989.
18. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with
community-acquired pneumonia. Am J Med 2006; 119: 877–883.
19. Saldias PF, Viviani GP, Pulgar BD et al. Prognostic factors and mortality
in immunocompetent adult patients hospitalized with community-
acquired pneumococcal pneumonia. Rev Med Chil 2009; 137: 1545–1552.
20. Wexler ID, Knoll S, Picard E et al. Clinical characteristics and out-
come of complicated pneumococcal pneumonia in a pediatric popula-
tion. Pediatr Pulmonol 2006; 41: 726–734.
21. Liapikou A, Ferrer M, Polverino E et al. Severe community-acquired
pneumonia: validation of the Infectious Diseases Society of America/
CMI Cillo´niz et al. Complicated pneumococcal pneumonia 1141
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 1134–1142
American Thoracic Society Guidelines to predict an intensive care
unit admission. Clin Infect Dis 2009; 48: 377–385.
22. Garcia-Vidal C, Ardanuy C, Tubau F et al. Pneumococcal pneumonia
presenting with septic shock: host- and pathogen-related factors and
outcomes. Thorax 2010; 65: 77–81.
23. Chibuk TK, Robinson JL, Hartﬁeld DS. Pediatric complicated pneumo-
nia and pneumococcal serotype replacement: trends in hospitalized
children pre and post introduction of routine vaccination with Pneumo-
coccal Conjugate Vaccine (PCV7). Eur J Pediatr 2010; 169: 1123–1128.
24. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by
serotype 19A: review of the literature and implications for future
vaccine development. Vaccine 2010; 28: 4249–4259.
25. de Roux A, Cavalcanti M, Marcos MA et al. Impact of alcohol abuse
in the etiology and severity of community-acquired pneumonia. Chest
2006; 129: 1219–1225.
26. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an inde-
pendent predictor of severity in community-acquired pneumonia. Am
J Med 2008; 121: 219–225.
27. Lim WS, van der Eerden MM, Laing R et al. Deﬁning community
acquired pneumonia severity on presentation to hospital: an interna-
tional derivation and validation study. Thorax 2003; 58: 377–382.
28. Gutierrez P, Closa D, Piner R et al. Macrophage activation in exacer-
bated chronic obstructive pulmonary disease with and without com-
munity-acquired pneumonia. Eur Respir J 2010; 36: 285–291.
29. Strassburg A, Luers A, Dalhoff K. Decreased apoptosis of pulmonary
PMN in COPD patients with community-acquired pneumonia. Clin
Respir J 2010; 4: 111–119.
30. Menendez R, Torres A, Zalacain R et al. Guidelines for the treatment
of community-acquired pneumonia: predictors of adherence and out-
come. Am J Respir Crit Care Med 2005; 172: 757–762.
1142 Clinical Microbiology and Infection, Volume 18 Number 11, November 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 1134–1142
